| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 230MM | +6% |
| Gross Profit | 177.7MM | - |
| Cost Of Revenue | 52.3MM | -5% |
| Operating Income | 101MM | +14% |
| Operating Expenses | 76.7MM | - |
| Net Income | 85.4MM | +4% |
| R&D | 21.3MM | +23% |
| G&A | 37.6MM | +7% |
| Amortization | 17.8MM | -13% |
| Interest Expense | 5.2MM | +16% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2024 financial and operating results on Tuesday, May 7, 2024, following the close of trading.
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
Halozyme Therapeutics (HALO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.